Evidence map›Paper›PMID 40514575›Full record

ReviewInternational journal of hematology2025

A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.

Yayoi Ueda, Toshiki Terao, Nobuharu Fujii, Tatsuji Mino, Saya Kubota, Kenta Hayashino, Kanako Fujiwara, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara and 5 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yayoi UedaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Toshiki TeraoDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Nobuharu FujiiDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan. nfujii@md.okayama-u.ac.jp.ORCID http://orcid.org/0000-0002-8043-7768
Tatsuji MinoDepartment of Hematology, Hiroshima City North Medial Center Asa Citizens Hospital, Hiroshima, Japan.
Saya KubotaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Kenta HayashinoDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Kanako FujiwaraDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Takumi KondoDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Keisuke SeikeDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Hideaki FujiwaraDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Noboru AsadaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Daisuke EnnishiDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Keiko FujiiDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Hideo TanakaDivision of Clinical Laboratory, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 50-year-old Japanese man with penta-drug refractory multiple myeloma (MM) was found to have stage IIIa cardiac immunoglobulin light-chain amyloidosis before idecabtagene vicleucel (ide-cel) therapy. Ide-cel therapy was started after careful consideration and hospital ethics committee approval. Grade 3 cytokine release syndrome and atrial flutter occurred in the acute phase after ide-cel infusion, but these were well-tolerated with supportive care in the intensive care unit. The patient achieved stringent complete response at day 60 and cardiac response at 9 months after ide-cel infusion with the addition of catheter ablation for sustained atrial flutter on day 133. He has maintained both hematological and cardiac remission for over 1 year since ide-cel therapy. This case highlights the effectiveness of ide-cel for disease control in heavily pretreated MM with cardiac amyloidosis.

Indexed as

AmyloidosisImmunoglobulin Light-chain AmyloidosisImmunotherapy, AdoptiveMultiple MyelomaHumansMaleMiddle AgedRecurrenceTreatment OutcomeCardiac AL amyloidosisIdecabtagene vicleucelMultiple myeloma

Identifiers

PMID40514575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.